Mednet Logo
HomeQuestion

Would you offer definitive chemoRT for NSCLC with histologically-proven contralateral station 11 nodal involvement?

2
3 Answers
Mednet Member
Mednet Member
Radiation Oncology · Cleveland Clinic

Contralateral hilar involvement is staged as N3 per AJCC 8th edition. In that regard, the management of an N3 patient should mimic that which we consider for any locally advanced IIIB or IIIC patient. Full staging including brain MRI is necessary. Pulmonary function testing including spirometry and ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · UCLA | VA Greater Los Angeles Healthcare System

Most importantly, get a biopsy to confirm the contralateral LN is real. If positive, these patients need both drugs and radiotherapy to have an optimal chance at long-term survival. Local control remains a problem which is why concurrent is favored over sequential. If safe, CRT can be optimized by d...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Alabama at Birmingham

Yes. Can cover PTV 95% at 95%, motion management (eg: phase gating), precise contours/expansions (crop CTV out of anatomy that is not at risk), and image guidance to minimize PTV expansion. Adaptive treatment (shrinking target volume as tumor responds) is not standard yet but is used occasionally at...

Register or Sign In to see full answer

Would you offer definitive chemoRT for NSCLC with histologically-proven contralateral station 11 nodal involvement? | Mednet